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(78.0%) could correctly statehowACTcouldbeused inmanagement
malaria in children under ﬁve.
Conclusion: Due to high level of unacceptability and affordabil-
ity ACT adoption for management of malaria in children less than
ﬁve years is still at startling level among their mothers. However,
ACT drugs should be made acceptable, affordable and available by
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Background: APOBEC3G potently controls HIV replication by
introducing G-to-A hypermutation. Genetic variants of APOBEC3G,
186H/R is associated with HIV/AIDS disease progression in adults.
However, the details of its effect in children remain unclear.
Methods & Materials: Rapid progressors (RPs) was deﬁned as
children who had AIDS-related symptoms (PCP, HIV encephalo-
pathy) before their second birthday. Long-term non-progressors
(LTNPs) were deﬁned as children, aged>8 years, maintaining
CD4%≥25%, and without cART. RPs and LTNPs were of 630 perina-
tally infected childrenwhowere enrolled in themulticenter studies
of Thailand and Cambodia.
APOBEC3G genotypes were determined by PCR-restriction frag-
ment length polymorphism method using genomic DNA samples.
APOBEC3G-mediated hypermutations were analyzed by sequenc-
ing of the vif/vpu genes from proviral DNAs.
Results: A total of 14 RPs and 24 LTNPs were enrolled. 50% of RP
and67%of LTNPwere female (p=0.3).Median ages at sample collec-
tion were 11.6 (4.7-15.1) years and 11.3 (10.0-12.3) years (p=0.3),
for the RPs and LTNPs, respectively. In the RP group, median age at
the ﬁrst AIDS-related symptom was 0.7 (0.4-1.2) years.
Frequency of APOBEC3G 186H/R genotypes, AA:AG:GG, in the
RPs was 100:0:0% whereas 83:17:0% (p=0.3) in the LTNPs. Hyper-
mutation of the vif-coding region were observed in none of the RP
and 12% of the LTNP (p=0.5). In contrast, hypermutations at the vpu
genes were not detected in both groups’ proviral DNAs.
Conclusion: We observed no signiﬁcant associations of the
APOBEC3G genotypes and G-to-A hypermutation rates between
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Background: Atazanavir/ritonavir(ATV/r) and tenofovir diso-
proxil fumarate(TDF) are recommended once-daily antiretroviral
therapy, particularly for second-line therapy. Their concomitant
use can lead to decrease in ATV and increase in TDF plasma con-
centration. There are limited data of efﬁcacy and safety of their
co-administration in children and adolescents.
Methods & Materials: Nineteen HIV-infected Thai children
aged 6-18years, body weight 25-50kg, and total bilirubin<2mg/dL
were enrolled. They were either PI-experienced with HIV-
RNA<50copies/ml or PI-naïve with HIV-RNA≥1,000copies/ml.
ATV(Reyataz®) 200mg/capsule with generic ritonavir
100mg/tablet, produced by the Thai Government Pharmaceutical
Organization, were co-administered with TDF and lamivudine
once daily. CD4, HIV-RNA, total bilirubin, creatinine, lipids, lumbar
